Circulating CD4+CD161+ T-cells normalize following MTX treatment.

Paulina Chalan (478974)
Bart-Jan Kroesen (64351)
Kornelis S. M. van der Geest (478975)
Minke G. Huitema (333143)
Wayel H. Abdulahad (333141)
Johan Bijzet (478976)
Elisabeth Brouwer (229171)
Annemieke M. H. Boots (120063)

Publication date

November 2013

DOI

10.1371/journal.pone.0079370.g002

Abstract

<p>(A) DAS28 and (B) the absolute number of CD4+CD161+ T-cells from RA patients at baseline (newly diagnosed; n=30), after 3 months (n=22) and 6 months (n=7) of MTX treatment (GEE analysis); (C) Comparison of the absolute number of CD4+CD161+ T-cells between HC (n=20) and RA patients at baseline (n=30; Mann- Whitney test) or RA patients at baseline (n=30) and RA patients after 3 months (n=26) or 6 months (n=12) of MTX treatment (Wilcoxon matched pairs test). Horizontal line in the box represents the median value. Boxes represent interquartile ranges and whiskers represent the actual range. Statistical significance is indicated as * p ≤ 0.05, ** p ≤ 0.001.</p